Nutriband Inc. is making significant strides in pharmaceutical drug delivery technology with its AVERSA platform, designed to improve the safety profile of transdermal drugs susceptible to abuse, particularly opioids like fentanyl.
The company's innovative technology can be incorporated into any transdermal patch and includes aversive agents to prevent misuse, diversion, and accidental exposure. This approach addresses a critical challenge in pain management and pharmaceutical safety by creating a mechanism to deter drug abuse while maintaining medication accessibility for patients who need it.
Nutriband has established a robust intellectual property strategy, with patents granted across multiple international markets including the United States, Europe, Japan, Korea, Russia, Canada, Mexico, Australia, and China. This comprehensive patent protection underscores the potential significance of their technological innovation.
Recent financial and strategic developments further validate the company's potential. In April 2024, Nutriband closed an $8.4 million financing round specifically to support commercial development of AVERSA Fentanyl. Additionally, the company formalized a long-term exclusive partnership with Kindeva Drug Delivery in February 2025, which will help expedite the pathway to market for their abuse-deterrent transdermal patch.
The AVERSA technology represents a potentially transformative approach to addressing the ongoing challenges of prescription drug misuse, offering a promising solution that could help mitigate risks associated with powerful pain medications while ensuring continued treatment options for patients with chronic pain.
